IO Biotech Announces Second Quarter Results for 2022
- Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma
- Announced initiation and dosing of first patient in Phase 2 Trial of IO102-IO103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-cohort basket trial
- Two presentations at ASCO highlighted current clinical trials with IO102-IO103 in combination with pembrolizumab and updated data cut from Phase 1/2 study of IO102-IO103 in combination with nivolumab showing high response rates in metastatic melanoma presented at AACR
- Strong balance sheet with $170.1 million cash runway to support multiple expected data readouts into mid-2024